Stifel Financial Corp purchased a new position in shares of Impax Laboratories, Inc. (NASDAQ:IPXL) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 636,863 shares of the specialty pharmaceutical company’s stock, valued at approximately $10,285,000. Stifel Financial Corp owned approximately 0.86% of Impax Laboratories as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Great West Life Assurance Co. Can lifted its holdings in shares of Impax Laboratories by 7.6% in the 1st quarter. Great West Life Assurance Co. Can now owns 103,506 shares of the specialty pharmaceutical company’s stock worth $1,304,000 after acquiring an additional 7,298 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Impax Laboratories by 11.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 15,029 shares of the specialty pharmaceutical company’s stock valued at $190,000 after purchasing an additional 1,588 shares during the last quarter. Comerica Bank grew its holdings in shares of Impax Laboratories by 3.6% during the 1st quarter. Comerica Bank now owns 81,477 shares of the specialty pharmaceutical company’s stock valued at $1,124,000 after purchasing an additional 2,869 shares during the last quarter. Karp Capital Management Corp bought a new position in shares of Impax Laboratories during the 1st quarter valued at $366,000. Finally, Parametric Portfolio Associates LLC grew its holdings in shares of Impax Laboratories by 88.4% during the 1st quarter. Parametric Portfolio Associates LLC now owns 149,249 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after purchasing an additional 70,044 shares during the last quarter. 86.26% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on the stock. BTIG Research reiterated a “buy” rating and issued a $27.00 target price (up previously from $20.00) on shares of Impax Laboratories in a research report on Saturday, September 23rd. Cantor Fitzgerald reissued a “buy” rating and issued a $25.00 price target on shares of Impax Laboratories in a research note on Monday, September 25th. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Impax Laboratories in a research report on Thursday, September 28th. They set a “neutral” rating and a $20.00 price target for the company. Citigroup Inc. upped their price target on shares of Impax Laboratories to $23.00 and gave the company a “buy” rating in a research report on Tuesday, September 19th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $23.00 price objective on shares of Impax Laboratories in a research note on Tuesday, September 19th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company’s stock. Impax Laboratories has a consensus rating of “Hold” and an average price target of $18.70.

Impax Laboratories, Inc. (NASDAQ:IPXL) opened at 21.05 on Wednesday. The company’s 50 day moving average price is $20.58 and its 200-day moving average price is $16.57. Impax Laboratories, Inc. has a one year low of $7.75 and a one year high of $25.70. The company’s market cap is $1.51 billion.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. The firm had revenue of $202.08 million during the quarter, compared to analysts’ expectations of $195.62 million. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The firm’s revenue for the quarter was up 17.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.21 EPS. On average, analysts forecast that Impax Laboratories, Inc. will post $0.70 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Stifel Financial Corp Purchases Shares of 636,863 Impax Laboratories, Inc. (IPXL)” was reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/stifel-financial-corp-purchases-shares-of-636863-impax-laboratories-inc-ipxl/1607843.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.